 Home > Active Ingredient News > Study of Nervous System > NEJM: New drug Donelizumab is expected to improve early-stage Alzheimer's disease

NEJM: New drug Donelizumab is expected to improve early-stage Alzheimer's disease

 Last Update: 2021-05-21
 Source: Internet
 Author: User

Tags

a hair

4 16 reduced

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Alzheimer's disease (AD) is the most common cause of dementia and one of the most serious problems faced by an aging population.

According to the "International Alzheimer's Disease Report", there were 47 million AD patients worldwide in 2015, and it is expected to increase to 131 million by 2050.

The neuropathological characteristics of AD are the deposition and winding of highly phosphorylated tau in neurons to form neurofibrillary tangles (NFTs), and the accumulation of amyloid β (Aβ).

At present, the long-term strategy to reduce dementia is mainly to identify disease risk factors as early as possible and intervene in the disease process, so as to delay the occurrence of the disease.

At present, the long-term strategy to reduce dementia is mainly to identify disease risk factors as early as possible and intervene in the disease process, thereby delaying the occurrence of the disease.

The basic principle of Donelizumab is that targeted deposition of plaque itself is necessary to clear the existing amyloid burden in the brain, rather than just preventing the deposition of new plaques or the growth of existing plaques.

Researchers conducted a phase 2 trial of donelimab in early symptomatic AD patients, who were determined to have tau and Aβ deposits on positron emission tomography (PET).

Test flow chart

A total of 257 patients were enrolled; 131 were assigned to receive donezumab and 126 received placebo.

At 76 weeks, the iADRS score of Donanizumab was -6.

At the same time, compared with placebo, donezumab reduced the rate of decline of iADRS by 32% (at 20 months).

Cognitive changes over time in early-stage AD patients treated with Donelizumab

Among early AD patients, the comprehensive score of Donelimab's cognitive ability and activities of daily living at 76 weeks is excellent, which is expected to bring hope to more elderly people.

references:

Mark A.

Donanemab in Early Alzheimer's Disease.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.